Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gene replacement therapies utilizing adeno-associated viral (AAV) vectors hold great promise for treating Duchenne muscular dystrophy (DMD). A related approach uses AAV vectors to edit specific regions of the DMD gene using CRISPR/Cas9. Here we develop multiple approaches for editing the mutation in dystrophic mdx 4cv mice using single and dual AAV vector delivery of a muscle-specific Cas9 cassette together with single-guide RNA cassettes and, in one approach, a dystrophin homology region to fully correct the mutation. Muscle-restricted Cas9 expression enables direct editing of the mutation, multi-exon deletion or complete gene correction via homologous recombination in myogenic cells. Treated muscles express dystrophin in up to 70% of the myogenic area and increased force generation following intramuscular delivery. Furthermore, systemic administration of the vectors results in widespread expression of dystrophin in both skeletal and cardiac muscles. Our results demonstrate that AAV-mediated muscle-specific gene editing has significant potential for therapy of neuromuscular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Smaller genome editing proteins, such as the S. aureus Cas9, C. jejuni Cas9 and newly identified CRISPR-Cas enzymes, may circumvent this issue 23,61-65 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 1,113
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle
Ervasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G., & Campbell, K. P. (1990) · Nature · doi:10.1038/345315a0 · Cited by 1,025
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Self-citationModular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
Harper, S. Q., Hauser, M. A., DelloRusso, C., Duan, D., Crawford, R. W., Phelps, S. F., Harper, H. A., Robinson, A. S., Engelhardt, J. F., Brooks, S. V., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-253 · Cited by 579
Self-citationLi, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Analyzing CRISPR genome-editing experiments with CRISPResso
Pinello, L., Canver, M. C., Hoban, M. D., Orkin, S. H., Kohn, D. B., Bauer, D. E., & Yuan, G.-C. (2016) · Nature Biotechnology · doi:10.1038/nbt.3583 · Cited by 459
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36612 · Cited by 389
Self-citationFlanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E., Howard, M. T., Sampson, J. B., Mendell, J. R., Wall, C., King, W. M., et al. (2009) · Human Mutation · doi:10.1002/humu.21114 · Cited by 321
rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice
Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., Finn, E., Adams, M. E., Froehner, S. C., Murry, C. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1439 · Cited by 307
Self-citationExpression of full-length and truncated dystrophin mini-genes in transgenic mdx mice
Phelps, S. F., Hauser, M. A., Cole, N. M., Rafael, J. A., Hinkle, R. T., Faulkner, J. A., & Chamberlain, J. S. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.8.1251 · Cited by 288
Self-citationEfficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251
Self-citationCellular and molecular mechanisms underlying muscular dystrophy
Rahimov, F., & Kunkel, L. M. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201212142 · Cited by 239
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Self-citationTibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury
Dellorusso, C., Crawford, R. W., Chamberlain, J. S., & Brooks, S. V. (2001) · Journal of Muscle Research & Cell Motility · doi:10.1023/a:1014587918367 · Cited by 212
Self-citationDifferential expression of dystrophin isoforms in strains of mdx mice with different mutations
Im, W. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.8.1149 · Cited by 212
Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human
Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C., et al. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.07.005 · Cited by 173
Jaynes, J. B., Chamberlain, J. S., Buskin, J. N., Johnson, J. E., & Hauschka, S. D. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.8.2855 · Cited by 172
Self-citationRegulation of creatine kinase induction in differentiating mouse myoblasts.
Chamberlain, J. S., Jaynes, J. B., & Hauschka, S. D. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.3.484 · Cited by 138
Self-citationEstablishment of Fibroblast Cultures
Takashima, A. (1998) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0201s00 · Cited by 132
Adeno-associated viral vectors do not efficiently target muscle satellite cells
Arnett, A. L., Konieczny, P., Ramos, J. N., Hall, J., Odom, G., Yablonka-Reuveni, Z., Chamberlain, J. R., & Chamberlain, J. S. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.38 · Cited by 112
Self-citationSparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy
Batchelor, C. L., & Winder, S. J. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.02.001 · Cited by 109
Immune Evasion by Muscle-Specific Gene Expression in Dystrophic Muscle
Hartigan-O'Connor, D., Kirk, C. J., Crawford, R., Mulé, J. J., & Chamberlain, J. S. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0496 · Cited by 101
Self-citationAnalysis of Muscle Creatine Kinase Regulatory Elements in Recombinant Adenoviral Vectors
Hauser, M. A., Robinson, A., Hartigan-O'Connor, D., Williams-Gregory, D., Buskin, J. N., Apone, S., Kirk, C. J., Hardy, S., Hauschka, S. D., & Chamberlain, J. S. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0089 · Cited by 99
Self-citationGene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95
Self-citationThe Polyproline Site in Hinge 2 Influences the Functional Capacity of Truncated Dystrophins
Banks, G. B., Judge, L. M., Allen, J. M., & Chamberlain, J. S. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000958 · Cited by 89
Self-citationProgress and prospects of gene therapy clinical trials for the muscular dystrophies
Bengtsson, N. E., Seto, J. T., Hall, J. K., Chamberlain, J. S., & Odom, G. L. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv420 · Cited by 70
Self-citationDesign and Testing of Regulatory Cassettes for Optimal Activity in Skeletal and Cardiac Muscles
Himeda, C. L., Chen, X., & Hauschka, S. D. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61737-982-6_1 · Cited by 40
Self-citationHu, C., Kasten, J., Park, H., Bhargava, R., Tai, D. S., Grody, W. W., Nguyen, Q. G., Hauschka, S. D., Cederbaum, S. D., & Lipshutz, G. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.99 · Cited by 33
Self-citationPurine-rich exon sequences are not necessarily splicing enhancer sequence in the dystrophin gene.
Ito, T., Takeshima, Y., Sakamoto, H., et al. (2001) · PubMed · doi:10.24546/00069787 · Cited by 2
Research works printed but not linked: 1
- Emery, A. E. H. & Muntoni, F. Duchenne Muscular Dystrophy 3rd edn, Oxford Univ. Press (2003).
Cited by
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546
Tabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
High levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431
Self-citation
Metadata
- Authors
- Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S.
- Affiliations
- University of Washington (US)
- Corresponding author
- Chamberlain, Joel R.
- Chamberlain, Jeffrey S.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-14
- Volume
- 8
- Issue
- 1
- Pages
- 14454-14454
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5316861
- OpenAlex
- W2588637030
- Cited by
- 387
- References
- 43
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 15 · 2023: 32 · 2022: 45 · 2021: 46 · 2020: 59 · 2019: 60 · 2018: 51 · 2017: 42
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-23)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Muscular Dystrophy Association (U54AR065139)
- University of Washington
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL122332)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR065139, R01AR044533)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD083091)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- Duchenne muscular dystrophy, CRISPR/Cas9 genome editing, dystrophin, adeno-associated virus vectors, single guide RNA, homologous recombination, gene replacement therapy, intramuscular administration, neuromuscular disorders
- MeSH terms
- Gene Editing, CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Dependovirus, Animals, Bacterial Proteins, Disease Models, Animal, Endonucleases, Genetic Vectors, Male, Mutation, Myocardium, Neuromuscular Diseases, Genetic Therapy, Dystrophin, Sequence Deletion, Mice, Inbred mdx, Muscle, Skeletal, Muscular Dystrophy, Duchenne, Mice, High-Throughput Nucleotide Sequencing, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.